Moderna Acquires OriCiro Genomics K.K. for $85 Million

Veracyte to Acquire C2i Genomics to Add Whole-Genome MRD Capabilities

January 8, 2024

Healthcare Services

Veracyte has reached a definitive agreement to acquire C2i Genomics, a minimal residual disease (MRD) detection company, to add whole-genome MRD capabilities to its diagnostics platform. Under the terms, Veracyte will pay $70 million in Veracyte shares at closing and up to an additional $25 million tied to future performance milestones, expected to close in the first quarter of 2024.

Gilead Sciences Acquires MiroBio

September 20, 2022

Biotechnology

Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.

Bionano Genomics Acquires BioDiscovery

October 12, 2021

Software

Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.

Kiromic Biopharma Acquires InSilico Solutions

July 26, 2021

Biotechnology

Kiromic Biopharma completed the acquisition of InSilico Solutions via a stock-swap, bringing an in‑house bioinformatics and AI team to support development of its outpatient allogeneic CAR‑T therapies for solid tumors. The deal transfers InSilico’s staff and intellectual assets to Kiromic and is intended to accelerate target/biomarker discovery, manufacturing and clinical development.

PerkinElmer to Acquire SIRION Biotech

June 22, 2021

Healthcare Services

PerkinElmer, Inc. entered into an agreement to acquire SIRION Biotech GmbH, a global provider of viral vector-based technologies for cell and gene therapies. The deal is expected to close in the third quarter of 2021 and will complement PerkinElmer’s Horizon Discovery portfolio and broader cell and gene research solutions.

Chimerix Acquires Oncoceutics

January 7, 2021

Biotechnology

Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.